Dr Karol talks to ecancer at ASH 2019 about his phase II study of 36 patients.
Venetoclax combined with high-dose cytarabine or high-dose cytarabine and idarubicin was found to be well tolerated and effective in children and young adults with relapsed or refractory AML.
Looking to the future, enrolment continues to refine estimates of response rate. The venetoclax window response was associated with BH3 dependence and end of cycle 1 response rates.
Targeting BCL-XL or FLT3 may improve response to combination therapy.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.